Myriad Genetics (MYGN)

Executive Summary

Myriad Genetics is a leading precision medicine diagnostics company, offering a comprehensive suite of tests for hereditary cancer, oncology, reproductive health, urology, and mental health. Leveraging a vast genetic database and over 30 years of experience, Myriad empowers clinicians with actionable insights to personalize patient care. The company has demonstrated resilience and growth, driven by expanding test volumes, new product launches, and strategic partnerships. Recent financial performance reflects strong demand for its hereditary cancer tests and growing adoption in reproductive health. With a focus on innovation and health equity, Myriad is well-positioned to capitalize on the expanding precision medicine market. Near-term growth is supported by upcoming catalysts, including new test launches and potential regulatory clearances, which could drive revenue acceleration and margin expansion.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance of the Myriad MyChoice CDx plus test for HRD detection in ovarian cancer75% success
• Q4 2026Expansion of reimbursement coverage for the Precise Liquid Biopsy test in multiple cancer types60% success
• Q2 2026Publication of positive clinical utility data for the GeneSight pharmacogenomic test in major depressive disorder80% success